Antibody Discovery
Rapidly advance lead molecules to the clinic by putting function first
Accelerate lead molecules to the clinic by profiling the B cell repertoire
The new Opto™ Plasma B Discovery 4.0 workflow on the Beacon® system advances from B cells to lead molecules in just 1 week. With this powerful workflow, you can:
- Advance from B cells to lead molecules by putting function first
- Succeed with difficult targets where traditional hybridoma and phage display methods have failed
- Increase campaign capacity by saving time and resources
Get a quick breakdown of this workflow from antibody expert, Anupam Singhal, PhD in his video tour.
Rapidly discover antibodies against difficult targets
In this GEN webinar, hear Genovac’s Patricia Odermatt and Iwona Budnicki present case studies and discuss how they utilized the Opto Plasma B Discovery workflow to rapidly discover antibodies against challenging targets, like GPCRs.
From patient sample to lead molecules in 18 days
In March 2020, scientists at Vanderbilt University found antibodies that neutralized SARS-CoV-2 in under three weeks, using our Opto™ Viral Neutralization Workflow. Two of those antibodies now comprise AstraZeneca’s promising antibody cocktail in Phase III Clinical Trials. Get a behind -the-scenes look at the workflow and hear from the Vanderbilt team about the process.
Find out more about how the Opto Plasma B Discovery workflow addresses your pain points. Just fill out the short form below and a specialist will reach out within 24 hours.